.png){kind=small}
History
CLECELL Co., Ltd. is a bioplatform company that creates a new era in the field of tissue engineering and regenerative medicine through state-of-the-art 3D bioprinting technologies.
Founding
Building a business
foundation
2016.12
Foundation of CLECELL, Co. Ltd.
2018.01
Patent Transfer from Harvard Medical School
Participation in KOTRA 2018 KOREA-FRANCE Startup Summit
2018.11
Research support agreement with Brigham and Women's Hospital(Harvard Medical University).
Corporate research lab(institute) establishment
2021.04
Completion of SNUH-IRB(Institutional Review Board) deliberation- Glioblastoma (GBM) 3D bioprinting cancer organoid model clinical research.
2019.05
Formation of Boston Bioprinting Consortium (BBC) consisting of members of doctors and professors from the Boston area of the United States
Certification as a Venture Company
2020.03
U-FAB (3D bioprinter) development
2020.06
3D artificial skin (U-skin) production protocol establishment
2020.08
3D Atopy Skin Model Development for Atopy Disease Treatment and Atopy Therapeutic Agent Screening Kit through Joint Research Agreement with Korea University Technology Holding Company
2020.09
Provision of U FAB 3D bioprinter to Harvard Medical School for joint research
2020.12
3D bioprinting cancer organoid model development (brain cancer, breast cancer, skin cancer)
Business model
expansion
2021.07
E. Technical transfer (TT) agreement with TPC Mechatronics PLC for CLECELL’s product (research model) U-FAB ACTIVO.